Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orencia

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Eliquis meets targets as long-term VTE therapy

Pfizer and BMS report positive phase III data for the Factor Xa inhibitor

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

Bristol-Myers Squibb (BMS) building

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

- PMLiVE

Ranbaxy recalls generic Lipitor in US

Several batches withdrawn after some products found to contain small particles of glass

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

- PMLiVE

BMS’ Orencia matches Humira in trial

Head-to-head study shows subcutaneous version as effective as Abbott's drug

Bristol-Myers Squibb (BMS) building

BMS cuts salesforce on revised Abilify deal

Nearly 500 jobs to go as US rights to schizophrenia blockbuster return to Otsuka

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links